Amyotrophic lateral sclerosis type 23 is a rare genetic form of ALS that affects nerve cells controlling movement. People with amyotrophic lateral sclerosis type 23 develop progressive weakness in the arms, legs, speech, and breathing. Symptoms usually begin in adulthood, but onset and speed can vary. The condition is lifelong and can shorten life, often due to breathing problems. Treatment focuses on symptom management, assistive devices, breathing support, and ALS medicines that may modestly slow progression.
Overview
Amyotrophic lateral sclerosis type 23Symptoms
Early symptoms of Amyotrophic lateral sclerosis type 23 often include muscle twitching, cramps, and weakness in an arm or leg. Over time, many develop slurred speech, trouble swallowing, stiffness, and breathing difficulty. Sensation stays normal, while thinking is usually unaffected.
Outlook and prognosis
For many living with Amyotrophic lateral sclerosis type 23, muscle weakness gradually progresses, often affecting walking, hand use, speech, and breathing over years. Survival varies; some live 2–5 years, while others live a decade or longer. Supportive care, respiratory support, and nutrition can prolong life and preserve independence.
Causes and risk factors
Amyotrophic lateral sclerosis type 23 often stems from an inherited ANXA11 gene change, usually autosomal dominant; some cases arise as new mutations. Aging and male sex increase risk. Smoking, prior head injury, physical exertion, and environmental toxins may modify onset and progression.
Genetic influences
Genetics play a major role in Amyotrophic lateral sclerosis type 23, which is caused by inherited changes in a single gene. Variants can run in families or appear for the first time. Genetic testing can confirm the diagnosis, guide counseling, and support family planning.
Diagnosis
Amyotrophic lateral sclerosis type 23 is diagnosed from progressive weakness with combined upper and lower motor neuron signs, supported by EMG. MRI and blood tests exclude mimics; genetic testing can confirm diagnosis of Amyotrophic lateral sclerosis type 23 in families.
Treatment and drugs
Treatment for Amyotrophic lateral sclerosis type 23 focuses on easing symptoms, protecting function, and supporting breathing, nutrition, and communication. Care often blends medicines for stiffness, cramps, saliva, and mood with physical, occupational, and speech therapy. Multidisciplinary clinics coordinate equipment, ventilatory support, and clinical trial options.
Symptoms
Small changes in muscle control can make everyday tasks—buttoning a shirt or turning a key—feel harder. In Amyotrophic lateral sclerosis type 23, these changes build over time as the nerves that activate muscles gradually stop working. You might notice small changes at first—subtle weakness, twitches, or cramps. Early symptoms of Amyotrophic lateral sclerosis type 23 often involve the hands, feet, speech, or swallowing, and later can affect breathing.
Dropping objects is common, and buttoning clothes can take longer. In ALS type 23, this often starts in one hand. Tasks that require grip or fine finger movements feel less steady.
Toes may drag when walking, causing stumbles or trips. With Amyotrophic lateral sclerosis type 23, you might notice one foot slapping the ground. Stairs and uneven sidewalks can become harder to manage.
Tight, painful cramps can strike the calves, hands, or thighs, especially at night. Stretching and gentle movement may ease them. Cramps can interrupt sleep and daytime routines.
Small, rippling twitches under the skin are common. They may be most noticeable in the arms, shoulders, or tongue. These twitches can come and go throughout the day.
How people usually first notice Amyotrophic lateral sclerosis type 23?
Many people first notice something is off when a hand feels clumsy, a foot starts to trip on flat ground, or speech becomes a bit slurred without a clear reason; these early changes in movement or voice are often the first signs of amyotrophic lateral sclerosis type 23. Over weeks to months, weakness tends to spread to nearby muscles, and loved ones may point out visible muscle thinning or twitching that you might not feel at first. Because ALS type 23 is genetic, some families become alert to how ALS is first noticed after a relative is diagnosed, prompting earlier checks when new weakness, cramps, or frequent falls appear.
Types of Amyotrophic lateral sclerosis type 23
Amyotrophic lateral sclerosis type 23 (ALS23) is a rare, genetic form of ALS linked to changes in the OPTN gene, which affects how nerve cells clear waste and manage inflammation. Because it’s inherited, families may see more than one relative affected, and onset can range from early to later adulthood. People may share the core features of ALS—weakness that spreads and affects speaking, swallowing, or breathing—but the course can vary by whether one or both OPTN copies carry a disease‑causing change. Researchers describe these categories to better understand patterns of the condition.
Heterozygous variant
Symptoms usually start in adulthood and may progress at a typical ALS pace. Weakness often begins in a hand or foot, then spreads to other limbs and bulbar muscles. Some families show slower change, while others follow a more classic course.
Biallelic variant
Having two disease‑causing OPTN changes can lead to earlier onset and faster progression. Weakness may spread quickly from limb muscles to speech and swallowing. Breathing muscles can be involved sooner than in other types of ALS23.
Motor‑predominant form
Muscle weakness, cramping, and twitching are the main features, with little or no sensory change. Reflexes may become brisk and stiffness can develop as upper motor pathways are affected. Daily tasks like buttoning shirts or climbing stairs often become harder first.
Bulbar‑onset form
Early changes center on speech and swallowing, such as slurred words or choking on liquids. Limb weakness follows over time. Family or friends sometimes notice speech clarity changes before hand or leg issues.
Lower‑limb onset
Weakness starts in the legs, showing up as tripping, foot drop, or trouble rising from a chair. Arm and bulbar muscles may be involved later. Even within the same type, intensity can range from mild to severe.
Upper‑limb onset
Early problems involve hand grip, fine finger tasks, or arm fatigue. Walking and swallowing can be normal at first and change later. For many, certain types stand out more than others.
With frontotemporal features
A subset develop changes in thinking or behavior alongside ALS symptoms. This can include planning difficulties, apathy, or social judgment changes. Loved ones may recognize certain types sooner than the person experiencing them.
Inflammation‑leaning course
Because OPTN helps control cell cleanup and inflammation, some experience a pattern that appears more inflammatory on testing. This does not replace core ALS features but may relate to faster change. If you notice one or more of these symptom types, bring it up at your next appointment.
What genetics can tell you about symptoms
Some people with ALS type 23 develop earlier muscle weakness, cramps, and stiffness because mutations in the SOD1 gene make a toxic form of the SOD1 protein that harms motor neurons. Certain variants tend to cause faster progression, while others bring a slower course.
Causes and risk factors
Amyotrophic lateral sclerosis type 23 is driven by a change in a single gene, which can be inherited or arise for the first time. The gene change sets your baseline risk and can affect when early symptoms of Amyotrophic lateral sclerosis type 23 begin. Risk also rises with older age, and men may be affected slightly more often than women. Smoking, past head injury, and long-term contact with pesticides or solvents may add risk. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Amyotrophic lateral sclerosis type 23 is a rare form of ALS that tends to appear in adulthood. That said, biology and environment work hand in hand. Below are non-genetic factors that can influence how likely ALS type 23 shows up or when it begins. We focus here on body-based and exposure-related risks, not lifestyle or inheritance.
Nerve cells become more vulnerable with age, which can make ALS type 23 more likely to appear over time. For many, early symptoms of Amyotrophic lateral sclerosis type 23 show up in adulthood.
Men have a slightly higher chance of developing ALS across studies. This pattern may influence who develops the condition.
Conception at an older father’s age increases the chance of new changes in sperm DNA. In rare cases, a new change could be the kind that leads to ALS type 23.
Older egg age is most known for chromosomal changes, but some studies suggest a small rise in new DNA changes at conception. This may very rarely raise the chance that the condition appears without a prior family history.
Genetic risk factors
In many families, Amyotrophic lateral sclerosis type 23 runs across generations because of a single gene change. Others have the condition because a new genetic change appears for the first time. Carrying a genetic change doesn’t guarantee the condition will appear; relatives can be affected at different ages and to different degrees. Genetic confirmation can be helpful when early symptoms of Amyotrophic lateral sclerosis type 23 begin in a family, and a genetics professional can explain what it means for you and your relatives.
Causative gene change: A harmful change (variant) in the ALS type 23 gene disrupts motor nerve function. This change is the direct genetic cause of the condition. Laboratory testing can detect this gene change.
Single-gene inheritance: ALS type 23 can pass from parent to child in a single-gene pattern. The specific pattern in a given family is best defined by a genetics review and test results. This helps explain who in the family may be at risk.
Family history clues: Having a close relative with ALS type 23 increases the chance of carrying the same gene change. People with the same risk factor can have very different experiences. Some relatives with the variant may never develop symptoms.
Variable onset, severity: Even within one family, ALS type 23 can start at different ages and progress at different speeds. This variability is part of why two relatives with the same variant may look quite different clinically. Doctors may use family patterns to discuss likely ranges, not exact timelines.
Possible de novo change: Sometimes the ALS type 23 gene change appears for the first time in a family. In that case, parents may test negative even though a child is affected. Confirming this helps refine future reproductive risk.
Genetic test confirmation: Identifying the specific ALS type 23 variant in an affected person confirms the genetic cause. Testing uses a blood or saliva sample and is often included in multi-gene ALS panels. Once found, targeted testing can clarify risk in adult relatives.
Lifestyle risk factors
Amyotrophic lateral sclerosis type 23 is a genetic form of ALS; lifestyle habits do not cause it, but they can influence symptom control, complication risks, and day‑to‑day function. Thoughtful choices around nutrition, movement, sleep, and habits may help preserve energy, reduce discomfort, and lower risks like malnutrition and infections. Below is a practical overview of how lifestyle affects Amyotrophic lateral sclerosis type 23 and the lifestyle risk factors for Amyotrophic lateral sclerosis type 23.
Maintaining a stable or slightly higher body weight can be linked to slower functional decline in ALS type 23. Calorie- and protein-dense meals and snacks help counter increased energy needs and reduce the risk of malnutrition.
As swallowing becomes less efficient, choosing softer textures, moist foods, and smaller, slower bites lowers choking and aspiration risk in ALS type 23. Upright posture during and after meals can further reduce aspiration and reflux.
Gentle aerobic and light resistance exercise can help maintain mobility, reduce deconditioning, and support mood in ALS type 23. Avoiding overexertion and allowing ample rest prevents excessive fatigue and post‑exercise weakness.
Daily stretching and range‑of‑motion work may lessen spasticity and cramps in ALS type 23. Keeping joints flexible helps with transfers and comfort and may delay contractures.
Risk prevention
For Amyotrophic lateral sclerosis type 23, there’s no proven way to stop the disease from starting, since it’s linked to inherited changes in a gene. Prevention is about lowering risk, not eliminating it completely. The focus is on spotting early symptoms of Amyotrophic lateral sclerosis type 23, keeping muscles and breathing as strong as possible, and reducing complications like infections or falls. Genetic counseling can also help families understand options for future pregnancies.
A genetics professional can explain inheritance, testing options, and family planning choices. This may include carrier testing for relatives and discussion of IVF with embryo testing.
Notice changes like weaker grip, foot drag, muscle cramps, or slurred speech and get checked promptly. Early confirmation allows faster access to supportive therapies and equipment.
Ongoing visits help track progression and adjust care plans. Timely referrals for therapy, breathing tests, or feeding support can prevent complications.
Gentle, regular movement can maintain function without overstraining muscles. A physical therapist can build a plan that protects joints and energy levels.
Transmission
Amyotrophic lateral sclerosis type 23 (ALS type 23) is not contagious. You can’t catch it from someone through touch, coughing, sex, blood contact, or shared items.
ALS type 23 is a genetic condition that can run in families when a changed gene is passed from a parent to a child, and it can also appear for the first time because of a new gene change. If you’re wondering how Amyotrophic lateral sclerosis type 23 is inherited, the genetic transmission of ALS type 23 varies by family, so a genetics professional can explain who in the family may be at risk and discuss testing.
When to test your genes
Consider genetic testing if you have ALS symptoms with a family history, especially early onset or multiple affected relatives, or if a clinician suspects a hereditary form. Testing can guide prognosis, eligibility for gene-informed trials, and family planning. People without symptoms but with a known family variant may consider testing after genetic counseling.
Diagnosis
For many, the first clues are day-to-day changes like hand weakness, leg tripping, or a softer voice that gradually gets harder to project. Doctors look for a consistent pattern of muscle weakness and nerve involvement, then use tests to rule out look-alike conditions and support the diagnosis. Early and accurate diagnosis can help you plan ahead with confidence. In practice, the diagnosis of Amyotrophic lateral sclerosis type 23 follows the same steps used for ALS in general, with genetic testing used to identify the specific subtype when appropriate.
The clinician checks strength, reflexes, muscle bulk, tone, and speech and swallowing. A mix of upper and lower motor neuron signs in different body regions supports ALS.
A focused history maps where weakness began and how it spread over time. Slow, steady progression without sensory loss is typical in ALS, including Amyotrophic lateral sclerosis type 23.
Tiny needles measure electrical activity in muscles to detect ongoing nerve loss. EMG showing widespread denervation supports ALS and helps exclude other nerve or muscle diseases.
Small electrical pulses test how well nerves carry signals. Results help rule out peripheral nerve conditions that can mimic ALS symptoms.
Stages of Amyotrophic lateral sclerosis type 23
Doctors often describe ALS in stages to help plan care and support. Amyotrophic lateral sclerosis type 23 generally follows the same pattern seen in most ALS, though the pace can differ widely from person to person. Sometimes answers come quickly, while other times it takes longer. What changes first usually depends on which muscles are affected at the start.
Early stage
Subtle changes show up in one region, like a weaker grip, tripping on curbs, or muscle cramps and twitching. Early symptoms of Amyotrophic lateral sclerosis type 23 may include fatigue and clumsier fine hand movements.
Regional spread
Weakness and stiffness extend to nearby muscle groups, making stairs, buttons, or lifting more challenging. Speech may grow a bit slurred or swallowing less smooth if throat muscles are involved.
Growing disability
Daily tasks take longer and may require braces, a cane, or other aids, and falls become more frequent. Breathing can feel harder with exertion as lung muscle strength drops, and doctors may track this with simple breathing tests.
Advanced stage
Mobility is highly limited, often requiring a wheelchair and help with most activities. Eating and speaking can be difficult, and noninvasive ventilation and feeding support may be discussed for Amyotrophic lateral sclerosis type 23.
End-of-life
Breathing muscles become very weak, and the risk of lung infections rises. Care tends to focus on comfort, symptom relief, and support for you and your loved ones.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many living with Amyotrophic lateral sclerosis type 23, early symptoms of ALS23 may start subtly—hand weakness when turning a key, tripping on a curb, or speech that gets a bit slurred after a long day. Over time, muscle weakness tends to spread to other areas, which can affect walking, hand use, speaking, and swallowing. Breathing muscles are usually involved later, and that stage is the main driver of serious complications.
Prognosis refers to how a condition tends to change or stabilize over time. ALS23 is generally progressive, but the tempo can vary—some people notice slower changes over several years, while others experience quicker declines. Average survival for ALS overall is often cited as 2 to 5 years from symptom onset, yet ALS23 can fall outside that window; some people live longer, especially with proactive respiratory and nutritional care. When breathing becomes difficult, assisted ventilation (noninvasive masks or, in some cases, tracheostomy) can extend both survival and comfort.
Everyone’s journey looks a little different. Quality of life can stay meaningful with adaptive tools, physical and speech therapy, and attention to mood and sleep. With the right support, the future can include time for work adaptations, family routines, and planning meaningful activities, even as care needs increase. Talk with your doctor about what your personal outlook might look like, including expected milestones, monitoring for respiratory changes, and whether genetic testing could inform care for ALS23.
Long-term effects
Amyotrophic lateral sclerosis type 23 is a progressive condition that affects nerve cells controlling muscles, leading to increasing weakness over time. Long-term effects vary widely, and the pace can differ from person to person. For many, this can mean growing challenges with walking, speaking, swallowing, and breathing that gradually change day-to-day life. Doctors often describe these as long-term effects or chronic outcomes, and planning ahead can help families prepare for future needs.
Weakness often starts in one area, like a hand or foot, and spreads to other muscle groups. Early symptoms of Amyotrophic lateral sclerosis type 23 can include grip weakness, frequent tripping, or foot drop. Over time, everyday tasks like buttoning clothes or climbing stairs become harder.
Walking may become unsteady, with shorter steps and frequent stumbles. Many eventually need canes, walkers, or a wheelchair to move safely. Falls can lead to injuries that further limit independence.
Speech can become slurred and softer as the muscles that control the tongue and voice weaken. Conversations may take more effort and be harder for others to understand. Some people eventually rely on communication devices or text-to-speech tools.
Swallowing can slow and become less coordinated, raising the risk of choking and chest infections. Meals may take longer, and weight loss can follow if eating becomes tiring. A feeding tube may be considered to maintain nutrition and reduce aspiration risk.
How is it to live with Amyotrophic lateral sclerosis type 23?
Living with Amyotrophic lateral sclerosis type 23 often means a gradual loss of muscle strength that reshapes everyday tasks—buttoning a shirt, climbing stairs, speaking clearly, or eventually breathing without support may require adaptive tools and help from others. Many people adjust routines to conserve energy, use mobility aids, and work with speech, physical, and respiratory therapists to stay as independent and safe as possible. Relationships can tighten as family and friends become care partners, which brings closeness and also stress; planning, honest communication, and respite support help everyone cope. While the condition progresses, thoughtful symptom management, accessible home modifications, and palliative care focused on comfort and choice can preserve quality of life and a sense of control.
Treatment and drugs
Treatment for Amyotrophic lateral sclerosis type 23 (ALS23) focuses on easing symptoms, maintaining function, and supporting breathing and nutrition, since no cure currently stops the disease. Doctors may use medicines that ease symptoms are called symptomatic therapies, such as drugs for muscle cramps, excess saliva, mood changes, and sleep issues, and may also consider approved ALS drugs like riluzole or edaravone, which can modestly slow decline in some people. Respiratory support ranges from breathing exercises and noninvasive ventilation at night to more advanced support as needed, while speech and swallow therapy, feeding tube placement, and high‑calorie nutrition help maintain weight and reduce choking risk. Physical and occupational therapy aim to keep you moving safely, with braces, walkers, or wheelchairs introduced as strength changes, and palliative care can help with comfort, mood, and planning at any stage. Not every treatment works the same way for every person, so care is typically coordinated by a multidisciplinary ALS clinic that adjusts the plan over time based on your goals and day‑to‑day needs.
Non-drug treatment
Day-to-day care for Amyotrophic lateral sclerosis type 23 often centers on keeping movement, breathing, and communication as strong and safe as possible. Beyond prescriptions, supportive therapies can help you stay active, adapt your home and routines, and plan ahead with your team. Many find that starting supportive care early makes tasks like walking, eating, and speaking easier for longer. Care is tailored because symptoms can progress at different speeds and in different orders.
A coordinated clinic brings neurology, rehab, respiratory, nutrition, and social work together. Shared visits reduce travel and streamline decisions.
Gentle, regular movement helps maintain flexibility and reduce stiffness. Targeted exercises are adapted as ALS type 23 changes strength over time.
Strategies and tools make dressing, bathing, and cooking safer and easier. Home modifications like grab bars and ramps reduce falls.
Techniques support clear speech and safer swallowing. Early training can smooth the transition to communication devices if speech declines.
Your genes may have an impact on how drugs work for you
Genes can change how your body processes ALS23 medicines—some people clear drugs quickly, others more slowly—affecting benefits and side effects. Pharmacogenetic testing can guide dose choices and supportive treatments, improving safety while we monitor response and adjust care.
Pharmacological treatments
Medications for Amyotrophic lateral sclerosis type 23 focus on slowing progression where possible and easing day-to-day symptoms like stiffness, cramps, drooling, mood changes, and sudden laughing or crying. There’s no cure yet, but a few disease-modifying options can modestly slow functional decline, and many supportive medicines improve comfort and independence. Not everyone responds to the same medication in the same way. Starting treatment soon after early symptoms of Amyotrophic lateral sclerosis type 23 appear may help preserve function, with choices tailored to your goals and what’s available in your country.
This long-standing ALS drug can modestly extend survival and delay ventilation. It’s taken by mouth; common effects include nausea, fatigue, or dizziness, and liver enzymes are checked regularly.
This antioxidant therapy can slow decline in function for some, especially earlier in the disease course. It’s given in cycles by infusion or as an oral formulation; headaches, bruising, and rash can occur, and availability varies by country.
Baclofen or tizanidine can ease stiffness and painful spasms to improve mobility and sleep. Drowsiness and muscle weakness are possible, so doses are adjusted slowly.
Mexiletine can reduce cramp frequency and intensity for many people with ALS. It may cause heart rhythm changes or stomach upset, so doctors often review heart history and monitor as needed.
Genetic influences
In Amyotrophic lateral sclerosis type 23, the condition is linked to a change in a single gene that can be passed through families or arise for the first time in someone with no known family history. Having a gene change doesn’t always mean you will develop the condition. When it does lead to illness, the age symptoms start and how quickly they progress can vary widely, even among relatives with the same change. A strong family history can be a clue that genes play a role, and genetic testing for Amyotrophic lateral sclerosis type 23 may help confirm the cause and clarify risks for siblings and children. Your care team may also recommend genetic counseling to explain what the results mean and to discuss options for family planning.
Is Amyotrophic lateral sclerosis type 23 genetic?
Genetics play a major role in Amyotrophic lateral sclerosis type 23, which is caused by inherited changes in a single gene. Variants can run in families or appear for the first time. Genetic testing can confirm the diagnosis, guide counseling, and support family planning.
Pharmacogenetics—how genetics influence drug effects
People living with Amyotrophic lateral sclerosis type 23 often take riluzole and several medicines to ease symptoms like muscle stiffness or mood changes; in some countries, edaravone is also used. Genes can influence how quickly you clear drugs such as riluzole or tizanidine, which can change how well they work and your risk of side effects. In everyday life, this can look like one person feeling very drowsy or light‑headed on a standard dose, while another seems to get little benefit unless the dose is adjusted. While not routine, pharmacogenetic testing for Amyotrophic lateral sclerosis type 23 may help with selecting or dosing certain symptom medicines (for example, some antidepressants or pain relievers) to reduce side effects. The specific gene change that causes Amyotrophic lateral sclerosis type 23 also guides research enrollment and may point to future gene‑directed treatments, but there is no approved gene‑specific therapy for this subtype yet. Your care team can weigh genetic results alongside your medical history, other medicines, and lifestyle factors like smoking to fine‑tune treatment.
Interactions with other conditions
Living with amyotrophic lateral sclerosis type 23 (ALS23) often means other health issues can change how symptoms feel day to day and shape the care plan. Doctors call it a “comorbidity” when two conditions occur together. In ALS overall, there can be overlap with frontotemporal dementia; while this varies by genetic subtype, new changes in planning, behavior, or mood deserve assessment because they can affect communication, safety, and decision‑making. If early symptoms of amyotrophic lateral sclerosis type 23 include swallowing or breathing weakness, pre‑existing lung conditions like asthma or COPD, sleep apnea, or heart disease can make shortness of breath worse, and common infections such as flu or pneumonia may trigger setbacks—keeping vaccines current and treating infections quickly can help. Conditions that affect nutrition and energy, including reflux, diabetes, weight loss, or low bone strength, may compound fatigue, muscle weakness, or fall risk, and anxiety or depression can intensify sleep and pain issues. Some medicines used for other illnesses—such as sedatives, certain sleep aids, or strong muscle relaxants—can suppress breathing or increase falls in ALS23, so it’s important that all your clinicians coordinate treatments and check for drug interactions.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of muscles weakening in mid-adulthood, hands growing clumsy, or feet catching on the ground, long before there was a name for it. Relatives might recall an aunt whose speech softened and slurred over a few years, or a grandfather who began using a cane and then a wheelchair. These lived stories set the stage for what we now recognize as Amyotrophic lateral sclerosis type 23, a genetic form of ALS linked to changes in a single gene.
First described in the medical literature as a familial pattern of ALS in several unrelated families, it stood out because weakness often began in the limbs and progressed over years rather than months. Initially understood only through symptoms, later tissue studies and nerve tests confirmed that the core problem was the gradual loss of motor neurons—the nerve cells that signal muscles to move.
In recent decades, knowledge has built on a long tradition of observation. Careful family trees showed that Amyotrophic lateral sclerosis type 23 could pass from one generation to the next. Advances in genetics then pinpointed the responsible gene and specific variants, clarifying that this is an inherited motor neuron disease with variable age of onset and speed of progression. Some families reported early symptoms of Amyotrophic lateral sclerosis type 23 in their 30s, while others noticed changes much later in life.
Over time, descriptions became more precise. Clinicians recognized both the everyday symptoms people felt—cramps, stiffness, tripping, changes in grip—and the features they observed on exam, such as brisk reflexes and muscle wasting. As genetic testing became more available in the EU and US, researchers identified more families worldwide, expanding the picture beyond the first reports and confirming that this subtype is rare but present across populations.
Medical classifications changed as researchers learned that ALS includes many genetic subtypes. Amyotrophic lateral sclerosis type 23 took its place among these, defined by its gene change, typical limb-onset weakness, and relatively slower course in some people. Not every early description was complete, yet together they built the foundation of today’s knowledge.
From early theories to modern research, the story of Amyotrophic lateral sclerosis type 23 shows how bedside observations, family histories, and laboratory work converge. Today, genetic counseling, careful symptom tracking, and supportive therapies reflect lessons drawn from decades of study, while ongoing research aims to turn this history into targeted treatments for those living with this form of ALS.